Status:
COMPLETED
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
Lead Sponsor:
Ain Shams University
Conditions:
Diabete Mellitus
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is investigating how the medication Empagliflozin affects the heart's structure and function in patients with heart disease. Empagliflozin is already used to treat diabetes and heart condit...
Detailed Description
Heart disease is a leading cause of illness worldwide, and new treatments that improve heart function can have a significant impact on patient health and longevity. This research could provide valuabl...
Eligibility Criteria
Inclusion
- Diabetic patients with anterior STEMI with reduced LVEF who underwent PPCI with successful revascularization and resulting into TIMI III flow and who are receiving SGLTi for the first time.
Exclusion
- patients who did not undergo primary PCI, those treated medically or had thrombolysis
- Non diabetic patient.
- Diabetic patient already on SGLTi
- STEMIs other than anterior.
- NSTEMI patients.
- Patients having valvular heart diseases.
- Patients having renal impairment.
- Patients with LV myopathies of non-ischemic origin.
Key Trial Info
Start Date :
July 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 17 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07169981
Start Date
July 12 2023
End Date
June 17 2025
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Egypt